المؤلفون: Haydu JE; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Maron JS; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Redd RA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Gallagher KME; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Fischinger S; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Barnes JA; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Hochberg EP; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Johnson PC; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Takvorian RW; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Katsis K; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Portman D; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Ruiters J; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Sechio S; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Devlin M; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Regan C; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Blumenthal KG; Department of Allergy and Immunology., Banerji A; Department of Allergy and Immunology., Judd AD; Department of Allergy and Immunology., Scorsune KJ; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., McGree BM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Sherburne MM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Lynch JM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Weitzman JI; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Lei M; Department of Pharmacy., Kotton CN; Department of Infectious Diseases, and., Dighe AS; Department of Pathology, Massachusetts General Hospital, Boston, MA., Maus MV; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Alter G; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Abramson JS; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Soumerai JD; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA.

المصدر: Blood advances [Blood Adv] 2022 Mar 22; Vol. 6 (6), pp. 1671-1683.

نوع المنشور: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

مواضيع طبية MeSH: COVID-19*/prevention & control , Leukemia, Lymphocytic, Chronic, B-Cell*/therapy, Adult ; Antibodies, Neutralizing ; COVID-19 Vaccines ; Humans ; Immunogenicity, Vaccine ; Prospective Studies ; SARS-CoV-2

المؤلفون: Al-Samkari H; Div of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA., Parnes AD; Hematology Division, Brigham and Womens Hospital, Boston, USA., Goodarzi K; Div of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA., Weitzman JI; Division of Hematology Oncology, Newton-Wellesley Hospital, Newton, USA., Connors JM; Hematology Division, Brigham and Women Hospital, Harvard Medical School, Boston, USA., Kuter DJ; Div of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA.

المصدر: Haematologica [Haematologica] 2021 Apr 01; Vol. 106 (4), pp. 1148-1157. Date of Electronic Publication: 2021 Apr 01.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Hematologic Neoplasms*/drug therapy , Neoplasms*/complications , Neoplasms*/drug therapy , Thrombocytopenia*/chemically induced , Thrombocytopenia*/drug therapy, Humans ; Receptors, Fc/therapeutic use ; Recombinant Fusion Proteins/therapeutic use ; Retrospective Studies ; Thrombopoietin/therapeutic use

المؤلفون: Brooks GA; Dana-Farber Cancer Institute, Boston, Massachusetts2Harvard Medical School, Boston, Massachusetts., Kansagra AJ; Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts., Rao SR; University of Massachusetts Medical School, Worcester5Bedford Veteran Affairs Medical Center, Bedford, Massachusetts., Weitzman JI; Mass General/North Shore Cancer Center, Danvers, Massachusetts., Linden EA; Harvard Medical School, Boston, Massachusetts6Mass General/North Shore Cancer Center, Danvers, Massachusetts., Jacobson JO; Dana-Farber Cancer Institute, Boston, Massachusetts2Harvard Medical School, Boston, Massachusetts.

المصدر: JAMA oncology [JAMA Oncol] 2015 Jul; Vol. 1 (4), pp. 441-7.

نوع المنشور: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Decision Support Techniques* , Hospitalization* , Palliative Care*, Antineoplastic Agents/*adverse effects , Neoplasms/*drug therapy, Aged ; Case-Control Studies ; Feasibility Studies ; Female ; Humans ; Logistic Models ; Male ; Massachusetts ; Multivariate Analysis ; Neoplasms/diagnosis ; Odds Ratio ; Predictive Value of Tests ; Registries ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome